Measuring cognition in advanced Alzheimer’s disease for clinical trials

  • F. A. Schmitt
  • D. Cragar
  • J. W. Ashford
  • B. Reisberg
  • S. Ferris
  • H.-J. Möbius
  • A. Stöffler
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 62)


Measurement of cognitive dysfunction and treatment response in the early stages of Alzheimer’s disease (AD) has used such scales as the MiniMental State Examination (MMSE) and the AD Assessment Scale (ADAS). With the exception of clinical rating scales, however, there are only a few objective measures of cognition for tracking progression in advanced AD. Given renewed interest in potential therapies for advanced AD, objective measures of cognition are important for the adequate evaluation of change due to AD progression or therapy. Several cognitive measures for advanced AD are reviewed. One measure, the Severe Impairment Battery (SIB) is reviewed in detail. Preliminary analyses from a trial of memantine show significant change on the SIB in memory (p < 0.001) and visuospatial functions (p < 0.02) over six-months with a trend for language and praxis. Data from a donepezil trial also highlight the importance of accurate assessment in advanced AD.


Severe Impairment Battery Severe Impairment Battery Score Thames Valley Test Company 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Albert M, Cohen C (1992) The test for severe impairment: an instrument for the assessment of patients with severe cognitive dysfunction. J Am Geriatr Soc 40: 449–453PubMedGoogle Scholar
  2. Auer SR, Reisberg B (1996) Reliability of the modified ordinal scales of psychological development: a cognitive assessment battery for severe dementia. Int Psychogeriatr 8: 225–231PubMedCrossRefGoogle Scholar
  3. Auer SR, Sclan SG, Yaffee RA, Reisberg B (1994) The neglected half of Alzheimer’s disease: cognitive and functional concomitants of severe dementia. J Am Geriatr Soc 42: 1266–1272PubMedGoogle Scholar
  4. Ashford JW, Schmitt FA (2001) Modeling the time-course of Alzheimer dementia.Curr Psychiatr Reports 3: 20–28CrossRefGoogle Scholar
  5. Ashford JW, Schmitt FA, Kumar V (1998) Diagnosis of Alzheimer’s disease.Psychiatr Ann 26: 262–268Google Scholar
  6. Barner EL, Gray SL (1998) Donepezil use in Alzheimer disease.Ann Pharmacother 32: 70–77PubMedCrossRefGoogle Scholar
  7. Bums A, Jacoby R, Levy R (1991) Progression of cognitive impairment in Alzheimer’s disease.J Am Geriatr Soc 39: 39–45Google Scholar
  8. Cummings JL, Benson DF (1992) Psychological dysfunction accompanying subcortical dementias.Annu Rev Med 3: 953–961Google Scholar
  9. Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, Gonzales N, Lai E, Massman P (2001) Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease.Dement Geriatr Cogn Disord 12: 295–300PubMedCrossRefGoogle Scholar
  10. Edland SD (2000) Blomqvist revisited: how and when to test the relationship between level and longitudinal rate of change.Stat Med 19: 1441–1452PubMedCrossRefGoogle Scholar
  11. Farlow M, Anand R, Messina J Jr, Hartman R, Veach J (2000) A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease.Eur Neuro l44: 236–241CrossRefGoogle Scholar
  12. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E (2001) A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease.Neurology 57: 613–620PubMedCrossRefGoogle Scholar
  13. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician.J Psychiatr Res 12: 189–198PubMedCrossRefGoogle Scholar
  14. Galasko DR, Schmitt FA, Jin S, Saxton J, Bennett D, Sano M, Ferris SH (2000) Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer’s disease.Neurobiol Aging 21 (lS): 168CrossRefGoogle Scholar
  15. Guy W. 028 CGI (1976) Clinical global impressions.In:Assessment manual for psychopharmacology, rev edn. National Institute of Mental Health, Rockville, Maryland, pp 217–222Google Scholar
  16. Harrell LE, Marson D, Chatterjee A, Parrish JA (2000) The severe mini-mental state examination: a new neuropsychologic instrument for the bedside assessment of severely impaired patients with Alzheimer’s disease.Alzheimer Dis Assoc Disord 14:168–175PubMedCrossRefGoogle Scholar
  17. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia.Br J Psychiatry 140: 566–572PubMedCrossRefGoogle Scholar
  18. Jarvik LF, Berg L, Bartus R, Heston L, Leith N, Phelps C, Shader R, Whitehouse P (1990) Clinical drug trials in Alzheimer’s disease: what are some of the issues?Alzheimer Dis Assoc Disord 4: 193–202PubMedCrossRefGoogle Scholar
  19. Knapp MI, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trial of high dose tacrine in patients with Alzheimer’s disease.JAMA 271: 985–991PubMedCrossRefGoogle Scholar
  20. Mackell JA, Ferris SH, Mohs R, Schneider L, Galasko D, Whitehouse P, et al (1997) Multicenter evaluation of new instruments for Alzheimer’s disease clinical trials: summary of results.Alzheimer Dis Assoc Disord 11 [Suppl 2]: 2–7Google Scholar
  21. Mattis S (1988) Dementia rating scale professional manual. Psychological Assessment Resources Inc, Odessa, FloridaGoogle Scholar
  22. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA (2000) Modelling mini mental state examination changes in Alzheimer’s disease.Stat Med 19: 1607–1616PubMedCrossRefGoogle Scholar
  23. Mesulam MM (1996) The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer’s disease.Prog Brain Res 109: 285–297PubMedCrossRefGoogle Scholar
  24. Mohs RC (1996) Comprehensive and neuropsychologic evaluations. The Alzheimer’s disease assessment scale.Int Psychogeriatr 8: 195–203PubMedCrossRefGoogle Scholar
  25. Mohs RC, Cohen L (1988) Alzheimer’s disease assessment scale (ADAS).Psychopharmacol Bull 24: 627–628PubMedGoogle Scholar
  26. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B (1998) Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease.Neurology 50: 1222–1230PubMedCrossRefGoogle Scholar
  27. Panisset M,Roudier M, Saxton J, Boller F (1994) Severe impairment battery ¨C a neuropsychological test for severely demented patients.Arch Neurol5l: 41--45CrossRefGoogle Scholar
  28. Peavy GM, Salmon DP, Rice VA, Galasko D, Samuel W, Taylor KI, Ernesto C, Butters N, Thai L (1996) Neuropsychological assessment of severely demeted elderly: the severe cognitive impairment profile.Arch Neurol 53: 367–372PubMedCrossRefGoogle Scholar
  29. Raskind MA, Peskind ER, Wessel T, Yuan W (2000) Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-l Study Group.Neurology 54: 2261–2268PubMedCrossRefGoogle Scholar
  30. Reisberg B (1988) Functional assessment staging (FAST). Psychopharmacol Bull 24: 653659 Reisberg B, Ferris SH, de Leon MJ, Crook T (1982) The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139: 1136–1139Google Scholar
  31. Reisberg B, Windscheif U, Ferris SH, Hingorani VH, Stoffler A, Mobius HJ (2000) Memantine in moderately severe to severe Alzheimer’s disease (AD): results of a placebo-controlled 6-month trial.Neurobiol Aging 21 (IS): S275CrossRefGoogle Scholar
  32. Rogers SL, Friedhoff LT (1996) The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a U.S. multicentre, randomized, double-blind, placebo controlled trial.Dementia 7: 293–303PubMedGoogle Scholar
  33. Rogers SL, Friedhoff LT (1998) Long term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study.Eur Neuropsychopharmaco l8: 67–75CrossRefGoogle Scholar
  34. Rogers SL, Doody RS, Mohs RC, Friedhoff LT (1998a) Donepezil improves cognition and global function in Alzheimer disease: a IS-week, double-blind, placebocontrolled study. Donepezil Study Group.Arch Intern Med 158: 1021–1031PubMedCrossRefGoogle Scholar
  35. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998b) A 24-week, doubleblind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group.Neurology 50: 136–145PubMedCrossRefGoogle Scholar
  36. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease.Am J Psychiatry 141: 1356–1364PubMedGoogle Scholar
  37. Rosier M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial.BMJ 318: 633–638Google Scholar
  38. Sano M, Growdon J, Klauber M, Erneston C, Schafer P, Woodbury P, Grundman M, Thai L (1995) Expanding the severity range of patients in clinical trials for Alzheimer’s disease: a multicenter clinical trial of selegiline and alpha tocopherol. Neurology 45 [Suppl 4]: A289Google Scholar
  39. Sano M, Ernesto C, Klauber M, Schafer K, Woodbury P, Grundman M, Thai L, Alzheimer’s Disease Cooperative Study Group (1996) Using the ADAS to assess change among moderately and severely impaired AD patients.J Int Neuropsychol Soc 2: 13Google Scholar
  40. Sano M, Growdon J, Thomas C, Ernesto K, Schafer K, Woodbury P, Grundman M, Thai L (1996) Evaluation of efficacy measures in clinical trials for Alzheimer’s disease: does psychometric test performance predict clinically relevant outcomes?Neurology 46: A218Google Scholar
  41. Saxton J, McGonigle-Gibson KL, Swihart AA, Miller VJ, Boller F (1990) Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery.J Consult Clin Psycho l2: 298–303Google Scholar
  42. Saxton J, Swihart A, McGonigle-Gibson KL, Miller VJ, Boller F (1990) Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery.Psychol Assess 2: 298–303CrossRefGoogle Scholar
  43. Saxton J, McGonigle KL, Swihart AA, Boller F (1993) The severe impairment battery manual. Thames Valley Test Company, Bury St. EdmundsGoogle Scholar
  44. Saxton J, McGonigle KL, Swihart AA, Boller F (1993) The Severe Impairment Battery.The University of Pittsburgh of the Commonwealth System of Higher Education (eds) Thames Valley Test Company, Suffolk, pp 1–16Google Scholar
  45. Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thai LJ (1997) The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study.Alzheimers Dis Assoc Disord l1 [Suppl 2]: 51–56CrossRefGoogle Scholar
  46. Scian SG, Reisberg B (1992) Functional assessment staging (FAST) in Alzheimer’s disease: reliability, validity, and ordinality. Int Psychoger 4 [Suppl1]: 55–69Google Scholar
  47. Volicer L, Hurley AC, Lathi DC, Kowall NW (1994) Measurement of severity in advanced Alzheimer’s disease.J Gerontol 49: M223–M226PubMedCrossRefGoogle Scholar
  48. Whitehouse PJ (1987) Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson’s disease and Alzheimer’s disease.Adv Neuro l45: 393–397Google Scholar
  49. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain.Science 215: 1237–1239PubMedCrossRefGoogle Scholar
  50. Wild KV, Kaye JA (1998) The rate of progression of Alzheimer’s disease in the later stages: evidence from the severe impairment battery.J Int Neuropsychol Soc 4: 512–516PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • F. A. Schmitt
    • 1
    • 2
    • 4
  • D. Cragar
    • 4
  • J. W. Ashford
    • 1
    • 3
  • B. Reisberg
    • 5
  • S. Ferris
    • 6
  • H.-J. Möbius
    • 6
  • A. Stöffler
    • 3
  1. 1.Sanders-Brown Center on Aging,Department of PsychiatryUniversity of Kentucky Medical CenterLexingtonUSA
  2. 2.Department of NeurologyUniversity of Kentucky Medical CenterLexingtonUSA
  3. 3.Veterans Administration Medical CenterUniversity of KentuckyLexingtonUSA
  4. 4.Department of PsychologyUniversity of KentuckyLexingtonUSA
  5. 5.Department of PsychiatryNew York University School of MedicineNew YorkUSA
  6. 6.R & D Pharma, Merz + CoFrankfurtFederal Republic of Germany

Personalised recommendations